Get the Stockscreener App
3.31
10.05%
-0.37
Engene Holdings Inc stock is traded at $3.31, with a volume of 64,674.
It is down -10.05% in the last 24 hours and up +2.80% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$3.68
Open:
$3.62
24h Volume:
64,674
Relative Volume:
0.95
Market Cap:
$164.05M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-0.7195
EPS:
-4.6001
Net Cash Flow:
$-26.70M
1W Performance:
-12.89%
1M Performance:
+2.80%
6M Performance:
-56.50%
1Y Performance:
-63.22%
1-Day Range:
$3.26
$3.66
1-Week Range:
$3.26
$3.98
52-Week Range:
$2.65
$11.00
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
3.31 | 164.05M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade) (NASDAQ:ENGN) - Seeking Alpha
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) to four newly-hired employees - BioSpace
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
JMP reiterates market outperform rating on enGene stock on clinical progress By Investing.com - Investing.com Nigeria
JMP reiterates market outperform rating on enGene stock on clinical progress - Investing.com Australia
Engene stock maintains buy rating at H.C. Wainwright on LEGEND trial - Investing.com
enGene Holdings Inc. adopts new employee stock plan By Investing.com - Investing.com Nigeria
enGene Holdings Reports Q2 2025 Financial Results - TipRanks
Engene stock maintains Outperform rating at Raymond James on strong execution By Investing.com - Investing.com South Africa
Engene stock maintains Outperform rating at Raymond James on strong execution - Investing.com India
EnGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025 - MarketScreener
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc reports results for the quarter ended April 30Earnings Summary - TradingView
EnGene Reports Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
enGene Holdings Inc. SEC 10-Q Report - TradingView
enGene Holdings CMO Resignation Announced - MSN
enGene Holdings Approves 2025 Employee Stock Purchase Plan - TipRanks
enGene Holdings Inc. adopts new employee stock plan - Investing.com
ENGENE HOLDINGS Earnings Preview: Recent $ENGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
enGene Holdings Expands with New Boston Lease - TipRanks
(ENGN) On The My Stocks Page - news.stocktradersdaily.com
enGene CMO Dr. Raj Pruthi to step down mid-June By Investing.com - Investing.com India
EnGene Chief Medical Officer Raj Pruthi to Step Down - marketscreener.com
enGene CMO Dr. Raj Pruthi Resigns - citybiz
enGene (ENGN) CMO Raj Pruthi Steps Down | ENGN Stock News - GuruFocus
enGene CMO Dr. Raj Pruthi to step down mid-June - Investing.com
enGene Announces the Resignation of its Chief Medical Officer - Business Wire
enGene to Present at the Jefferies Global Healthcare Conference - BioSpace
enGene appoints new Chief Global Commercialization Officer By Investing.com - Investing.com South Africa
enGene Names Amy Pott as Chief Global Commercialization Officer - citybiz
enGene appoints new Chief Global Commercialization Officer - Investing.com Australia
enGene (ENGN) Appoints Amy Pott as New Chief Global Commercialization Officer | ENGN Stock News - GuruFocus
EnGene Names Amy Pott As Chief Global Commercialization Officer - marketscreener.com
When (ENGN) Moves Investors should Listen - news.stocktradersdaily.com
Head-To-Head Review: enGene (NASDAQ:ENGN) vs. ImmunityBio (NASDAQ:IBRX) - Defense World
Where are the Opportunities in (ENGN) - news.stocktradersdaily.com
Is enGene Holdings (NASDAQ:ENGN) Using Too Much Debt? - simplywall.st
(ENGN) Trading Signals - news.stocktradersdaily.com
Citizens JMP reiterates Engene stock with $18 target By Investing.com - Investing.com Nigeria
Citizens JMP reiterates Engene stock with $18 target - Investing.com
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
enGene to Participate in Upcoming May 2025 Investor Conferences - BioSpace
enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35% - Yahoo Finance
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
(ENGN) Technical Data - news.stocktradersdaily.com
enGene (NASDAQ:ENGN) & Innate Pharma (OTCMKTS:IPHYF) Head-To-Head Survey - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts - Defense World
Trend Tracker for (ENGN) - news.stocktradersdaily.com
Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Engene Holdings Inc Stock (ENGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 08 '24 |
Buy |
6.60 |
800 |
5,278 |
2,470,633 |
| Cooper Ronald Harold Wilfred | Chief Executive Officer |
Sep 27 '24 |
Buy |
5.70 |
10,000 |
57,000 |
10,000 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):